Alberto Martini1, Shivaram Cumarasamy2, Alp Tuna Beksac2, Ronney Abaza3, Daniel D Eun4, Akshay Bhandari5, Ashok K Hemal6, James R Porter7, Ketan K Badani8. 1. Department of Urology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA. Electronic address: a.martini.md@gmail.com. 2. Department of Urology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA. 3. Robotic Urologic Surgery, OhioHealth Dublin Methodist Hospital, Columbus, OH, USA. 4. Department of Urology, Temple University School of Medicine, Philadelphia, PA, USA. 5. Division of Urology, Columbia University at Mount Sinai, Miami Beach, FL, USA. 6. Department of Urology, Wake Forest School of Medicine, Winston-Salem, NC, USA. 7. Swedish Urology Group, Seattle, WA, USA. 8. Department of Urology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA. Electronic address: ketan.badani@mountsinai.org.
Abstract
BACKGROUND: Decreased functional outcome after partial nephrectomy is associated with overall mortality. OBJECTIVE: To create a model that predicts ≥25% reduction from baseline estimated glomerular filtration rate (eGFR) in patients undergoing robot-assisted partial nephrectomy (RAPN) and to investigate the role of acute kidney injury (AKI) in this patient population. DESIGN, SETTING, AND PARTICIPANTS: A total of 999 patients were identified from a multi-institutional database. Renal function was defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for chronic kidney disease (CKD). AKI was defined as >25% reduction in eGFR from pre-RAPN period to discharge. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: A nomogram to predict significant eGFR reduction (≥25% from baseline) in the time-frame between 3 and 15mo after RAPN was built based on the coefficients of Cox survival function that ultimately included age, sex, Charlson comorbidity index, baseline eGFR, RENAL nephrometry score, AKI in patients with normal baseline renal function, and AKI on CKD. Such landmark analysis was chosen in order to account for eGFR fluctuations occurring within the first 3mo of RAPN. The proportional hazard assumption was evaluated through the Schönfeld test. Internal validation was performed using the leave-one-out cross validation. Calibration was graphically investigated. The decision curve analysis (DCA) was used to evaluate the net clinical benefit. RESULTS AND LIMITATIONS: Median (interquartile range [IQR]) age at surgery was 61yr (51, 68). Overall, 146 patients experienced significant eGFR reduction; median follow-up for survivors was 12.4mo. The 15-mo probability of significant eGFR reduction was 19%. All variables fitted into the model, including AKI in patients with normal renal function (hazard ratio [HR]: 4.51; 95% confidence interval [CI]: 3.12, 6.60; p<0.001) and AKI on CKD (HR: 4.90; 95% CI: 2.17, 11.1; p<0.001), emerged as predictors of significant eGFR reduction (all p≤0.048) and were considered to build a nomogram. The internally validated c index was 73%. The model demonstrated excellent calibration and a net benefit at the DCA with probabilities ≥4%. CONCLUSIONS: We developed a nomogram that accurately predicts significant eGFR reduction after RAPN. This model may serve as a tool for early identification of patients at high risk for significant renal function decline after surgery. PATIENT SUMMARY: We have developed a model for the prediction of renal function loss after partial nephrectomy for renal cancer.
BACKGROUND: Decreased functional outcome after partial nephrectomy is associated with overall mortality. OBJECTIVE: To create a model that predicts ≥25% reduction from baseline estimated glomerular filtration rate (eGFR) in patients undergoing robot-assisted partial nephrectomy (RAPN) and to investigate the role of acute kidney injury (AKI) in this patient population. DESIGN, SETTING, AND PARTICIPANTS: A total of 999 patients were identified from a multi-institutional database. Renal function was defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for chronic kidney disease (CKD). AKI was defined as >25% reduction in eGFR from pre-RAPN period to discharge. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: A nomogram to predict significant eGFR reduction (≥25% from baseline) in the time-frame between 3 and 15mo after RAPN was built based on the coefficients of Cox survival function that ultimately included age, sex, Charlson comorbidity index, baseline eGFR, RENAL nephrometry score, AKI in patients with normal baseline renal function, and AKI on CKD. Such landmark analysis was chosen in order to account for eGFR fluctuations occurring within the first 3mo of RAPN. The proportional hazard assumption was evaluated through the Schönfeld test. Internal validation was performed using the leave-one-out cross validation. Calibration was graphically investigated. The decision curve analysis (DCA) was used to evaluate the net clinical benefit. RESULTS AND LIMITATIONS: Median (interquartile range [IQR]) age at surgery was 61yr (51, 68). Overall, 146 patients experienced significant eGFR reduction; median follow-up for survivors was 12.4mo. The 15-mo probability of significant eGFR reduction was 19%. All variables fitted into the model, including AKI in patients with normal renal function (hazard ratio [HR]: 4.51; 95% confidence interval [CI]: 3.12, 6.60; p<0.001) and AKI on CKD (HR: 4.90; 95% CI: 2.17, 11.1; p<0.001), emerged as predictors of significant eGFR reduction (all p≤0.048) and were considered to build a nomogram. The internally validated c index was 73%. The model demonstrated excellent calibration and a net benefit at the DCA with probabilities ≥4%. CONCLUSIONS: We developed a nomogram that accurately predicts significant eGFR reduction after RAPN. This model may serve as a tool for early identification of patients at high risk for significant renal function decline after surgery. PATIENT SUMMARY: We have developed a model for the prediction of renal function loss after partial nephrectomy for renal cancer.
Authors: Carlo Andrea Bravi; Emily Vertosick; Nicole Benfante; Amy Tin; Daniel Sjoberg; A Ari Hakimi; Karim Touijer; Francesco Montorsi; James Eastham; Paul Russo; Andrew Vickers Journal: Eur Urol Date: 2019-05-10 Impact factor: 20.096
Authors: Alessandro Tafuri; Michele Marchioni; Clara Cerrato; Andrea Mari; Riccardo Tellini; Katia Odorizzi; Alessandro Veccia; Daniele Amparore; Aliasger Shakir; Umberto Carbonara; Andrea Panunzio; Federica Trovato; Michele Catellani; Letizia M I Janello; Lorenzo Bianchi; Giacomo Novara; Fabrizio Dal Moro; Riccardo Schiavina; Elisa De Lorenzis; Paolo Parma; Sebastiano Cimino; Ottavio De Cobelli; Francesco Maiorino; Pierluigi Bove; Fabio Crocerossa; Francesco Cantiello; David D'Andrea; Federica Di Cosmo; Francesco Porpiglia; Pasquale Ditonno; Emanuele Montanari; Francesco Soria; Paolo Gontero; Giovanni Liguori; Carlo Trombetta; Guglielmo Mantica; Marco Borghesi; Carlo Terrone; Francesco Del Giudice; Alessandro Sciarra; Andrea Galosi; Marco Moschini; Shahrokh F Shariat; Marta Di Nicola; Andrea Minervini; Matteo Ferro; Maria Angela Cerruto; Luigi Schips; Vincenzo Pagliarulo; Alessandro Antonelli Journal: World J Urol Date: 2022-10-06 Impact factor: 3.661
Authors: Ugo G Falagario; Alberto Martini; John Pfail; Patrick-Julien Treacy; Kennedy E Okhawere; Bheesham D Dayal; John P Sfakianos; Ronney Abaza; Daniel D Eun; Akshay Bhandari; James R Porter; Ashok K Hemal; Ketan K Badani Journal: Transl Androl Urol Date: 2020-04
Authors: Robert J Ellis; Sharon J Del Vecchio; Kevin M J Gallagher; Danielle N Aliano; Neil Barber; Damien M Bolton; Etienne T S Chew; Jeff S Coombes; Michael D Coory; Ian D Davis; James F Donaldson; Ross S Francis; Graham G Giles; Glenda C Gobe; Carmel M Hawley; David W Johnson; Alexander Laird; Steve Leung; Manar Malki; David J T Marco; Alan S McNeill; Rachel E Neale; Keng L Ng; Simon Phipps; Grant D Stewart; Victoria M White; Simon T Wood; Susan J Jordan Journal: J Am Soc Nephrol Date: 2020-04-01 Impact factor: 10.121